Table 2.

Microbiologic Cure by Anatomic Site and Study Population, Gyrase A Serine 91 Neisseria gonorrhoeae Ciprofloxacin Treatment Study

Study Population and Statistics	Cervical/Urethral	Rectal	Pharyngeal	All Anatomic Sites
Intent-to-treata
Number of infections with microbiological cure, n	38	81	35	154
Number of infections, n	39	89	40	168
Microbiological cure, %	97.4	91	87.5	91.7
95% CI, %	90.4–100.0	85.0–100.0	77.0–100.0	87.6–100.0
Microbiological intent-to-treatb
Number of infections with microbiological cure, n	33	74	14	121
Number of infections, n	34	79	16	129
Microbiological cure, %	97.1	93.7	87.5	93.8
95% CI, %	89.1–100.0	88.0–100.0	69.5–100.0	89.6–100.0
Per-protocolc
Number of infections with microbiological cure, n	30	73	14	117
Number of infections, n	30	73	14	117
Microbiological cure, %	100	100	100	100
95% CI, %	90.5–100.0	96.0–100.0	80.7–100.0	97.5–100.0

Abbreviation: CI, confidence interval.

^aThe intent-to-treat population included all infections in subjects enrolled who had a culture-positive N. gonorrhoeae infection at enrollment regardless of repeat gyrA serine 91 N. gonorrhoeae result at enrollment.

^bThe microbiological intent-to-treat population for the specified anatomic site included only those with a wild-type gyrA serine 91 N. gonorrhoeae culture-positive result at enrollment.

^cThe per-protocol population for the specified anatomic site included those in the microbiological intent-to-treat population with a follow-up culture result collected within the protocol-specified follow-up visit window (ie, 5–10 days after enrollment) and who did not receive any contraindicated medication or systemic antibiotic prior to the follow-up visit.